drugset / Trial / NCT02015728
Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This research study is a Feasibility clinical trial. In this trial, researchers are trying to figure out whether a medication can be chosen based on rapid testing done on tumor tissue. Information from a feasibility or pilot trial will hopefully help researchers plan larger trials in the future to determine the effect of this therapy.
Timeline
- Start
- 2013-12
- Primary completion
- 2016-11
- Completion
- 2017-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Erlotinib | Small molecule | 85 mg/m2 | Oral |
| Subject | Everolimus | Small molecule | 3 mg/m2 | Oral |
| Subject | Sorafenib | Small molecule | 150 mg/m2 | Oral |
| Subject | dasatinib anhydrous | Small molecule | 60 mg/m2 | Oral |
| Background | Etoposide | Small molecule | 50 mg/m2 | Oral |
| Background | Temozolomide | Small molecule | 150 mg/m2 | Oral |